Active Ingredient(s): Bempedoic Acid + Ezetimibe
FDA Approved: * February 26, 2020
Category: Cholesterol

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Nexlizet Overview

Bempedoic acid/ezetimibe, sold under the brand name Nexlizet among others, is a fixed-dose combination medication used as an adjunct with diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.[1] It is a combination of bempedoic acid and ezetimibe.[1][2] The most common side effects are ...

Read more Nexlizet Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Nexlizet Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Bempedoic Acid + Ezetimibe
  • Tablet: 180mg + 10mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Nexlizet: (1 result)

Sorted by National Drug Code
  • 72426-818 Nexlizet Oral Tablet, Film Coated by Esperion Therapeutics, Inc.

Drugs with one or more similar ingredients: (9 results)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 16 May 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA